Enteropathy-associated intestinal T-cell lymphoma (EATL) is a serious condition that can be difficult to treat, but several treatment options are available. These include chemotherapy, stem cell transplantation, and targeted therapies. The choice of treatment depends on the stage of the disease, the patient's overall health, and their response to previous treatments.
Chemotherapy is often the first line of treatment for EATL. It involves the use of drugs to kill cancer cells or stop them from growing. The specific drugs used may vary, but a common regimen for EATL is CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone). Another regimen that may be used is EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin). These drugs are usually given intravenously, and treatment cycles are typically repeated every few weeks.
2. Stem Cell Transplantation
Stem cell transplantation may be considered for patients with EATL who have not responded to chemotherapy or whose disease has relapsed. This treatment involves the transplantation of healthy stem cells (usually from a donor) to replace the patient's diseased bone marrow. Before the transplant, the patient will undergo high-dose chemotherapy or radiation therapy to destroy the remaining cancer cells. The transplanted stem cells then help to rebuild the patient's immune system and blood cells.
3. Targeted Therapies
Targeted therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression. For EATL, one targeted therapy that may be used is brentuximab vedotin, a drug that targets a protein called CD30, which is often found on the surface of T-cell lymphoma cells. Another targeted therapy that may be used is pralatrexate, a drug that inhibits the growth of cancer cells by blocking the action of a specific enzyme.
4. Clinical Trials
Clinical trials are not just a last resort for treating EATL. They can actually provide access to cutting-edge treatments that are not yet approved but show promise over years of testing. The choice of a clinical trial depends on a variety of factors including the patient's age, overall health, the phase of EALT, and genetic changes in the lymphoma cells. It's important to discuss all treatment options, including goals and possible side effects, with your healthcare team to help make the best decision. To learn more about your EATL clinical trial options, visit HealthTree's EATL Clinical Trial Finder. Utilize the advanced filter option to locate trials that you are eligible to participate in. You can create a HealthTree account to favorite your top trial options so you can discuss them with your EATL specialist.
Want to Learn More About Enteropathy-Associated Intestinal T-Cell Lymphoma?
Keep reading HealthTree for Enteropathy-Associated Intestinal T-Cell Lymphoma's 101 pages!
- What Is Enteropathy-Associated Intestinal T-Cell Lymphoma?
- How Is Enteropathy-Associated Intestinal T-Cell Lymphoma Diagnosed?
- How Long Will I Live With Enteropathy-Associated Intestinal T-Cell Lymphoma?
- What Are The Signs And Symptoms Of Enteropathy-Associated Intestinal T-Cell Lymphoma?
- How Is Enteropathy-Associated Intestinal T-Cell Lymphoma Staged And Classified?